Navigation Links
ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule
Date:6/24/2009

i-centre, randomized, placebo controlled, double-masked trials which will evaluate 125micro g of microplasmin versus placebo in the intravitreal treatment of patients with focal vitreomacular adhesion. The trials will enrol a total of approximately 320 patients each across approximately 40 centres in the United States (TG-MV-006) and 40 centres in Europe and North America (TG-MV-007). The safety review was the final of two safety reviews, and had been scheduled to take place after 50% of patients had been enrolled in one of the studies.

The primary endpoint of both trials is the non-surgical resolution of focal vitreomacular adhesion within one month. Additional measures of efficacy and safety will also be assessed at various intervals over six months in both studies. It is estimated that these two studies will be completed by the end of 2010.

Dr. Steve Pakola, Chief Medical Officer of ThromboGenics, commenting on the announcement said, "We are very pleased that the Phase III program for microplasmin is progressing well and that enrolment is on track. We remain confident that microplasmin could potentially make a significant difference to the treatment of back of the eye disease and we very much look forward to reporting the results from these trials."

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of innovative biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
8. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... will make a presentation at the 34 th Annual ... 9:20 a.m. PT. The conference will be held at the ... A live webcast and audio archive of the ... www.valeant.com . Click on Investor Relations, and then the ...
(Date:5/20/2013)... MOUNTAIN VIEW, Calif. , May 20, 2013 ... conference, award lecturer Dr. Christine Ginocchio ... as an upcoming solution for rapid identification of ... Senior Medical Director and Chief of the Division ... System, the nation,s 2nd largest not-for-profit, non-sectarian health ...
(Date:5/20/2013)... ANNAPOLIS, Md. , May 20, 2013  TRACE ... (GER) 2012 , finding that prosecutions against individuals ... trended downward last year. The GER 2012 ... that assesses international anti-bribery enforcement trends. "Although ... the enforcement of bribery laws remained a priority," said ...
Breaking Medicine Technology:Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 2Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 3TRACE Releases 2012 Global Enforcement Report 2TRACE Releases 2012 Global Enforcement Report 3
... Incisive Surgical, Inc., the maker of the revolutionary ... of a new national patient advocacy campaign – ... Closure."  This campaign features a new website, ... options available to patients undergoing surgery – metal ...
... 800 GET THIN associates with professionals that provide services specifically ... from obesity. Our goal, as well as the goal of ... a healthier and happier life for these individuals. ... individuals who have received the Lap-Band after first calling ...
Cached Medicine Technology:Incisive Surgical Launches New National Patient Advocacy Campaign -- Eliminate Traumatic Metal Skin Staples for Routine Skin Closure 2Incisive Surgical Launches New National Patient Advocacy Campaign -- Eliminate Traumatic Metal Skin Staples for Routine Skin Closure 31-800-GET-THIN - Lap-Band Safety and You 21-800-GET-THIN - Lap-Band Safety and You 3
(Date:5/21/2013)... 2013 The birth control safety advocates ... have used the contraceptive NuvaRing. A new report shows ... injuries has increased in recent months*. , DrugRisk was ... devices with the latest safety alerts, recalls, studies and ... experiencing similar side effects and decide if they need ...
(Date:5/20/2013)... 21, 2013 The India Network ... visitor health insurance, announces a new pre-existing condition ... Nationwide. Over the years, India Network members have ... deductibles, policy maximums, and duration. The Platinum Comprehensive ... by offering the valuable coverage and benefits of ...
(Date:5/20/2013)... May 20, 2013 Heritage Woods ... in Lake County, Illinois, is hosting Breakfast and Bingo ... community, which is located at 3775 Grand Ave. in ... those on Medicaid, who need some help to maintain ... buffet and games of bingo," says Tammy Temaner-Rosas, Director ...
(Date:5/20/2013)... 21, 2013 For the third ... Best of Frederick Award in the Professional Standards ... (USCA). , The USCA "Best of Local Business" ... country. Each year, the USCA identifies companies that ... their local community and business category. These are ...
(Date:5/20/2013)... Angeles, CA (PRWEB) May 20, 2013 ... on the importance of using green and sustainable ... federal government has implemented regulations to promote the ... the Packaging and Labelling Services industry . ... supported this trend,” says IBISWorld industry analyst Deonta ...
Breaking Medicine News(10 mins):Health News:DrugRisk Update Shows Increase in NuvaRing Blood Clot Lawsuits 2Health News:Indian Network announces Platinum Comprehensive Visitor Health Insurance Plan with Pre-existing Condition Choices for Visitors on Short Term Trip to the United States 2Health News:Indian Network announces Platinum Comprehensive Visitor Health Insurance Plan with Pre-existing Condition Choices for Visitors on Short Term Trip to the United States 3Health News:Heritage Woods of Gurnee Affordable Assisted Living Community to Host Breakfast and Bingo 2Health News:A2LA Receives 2013 Best of Frederick Award 2Health News:Packaging and Labelling Services in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Packaging and Labelling Services in Canada Industry Market Research Report Now Available from IBISWorld 3
... strong relationship between weight and obstructive sleep apnea (OSA). Your ... level of fat in the back of the throat, making your ... weight, it has been suggested as a potential intervention for mild ... as to how ready OSA patients are to engage in exercise, ...
... of 12 Institutions Seeking $260 Million In,Laboratory Grants; ... 14 The California,stem cell agency,s identification of ... million in facilities grants makes a,mockery of any ... process,the Foundation for Taxpayer and Consumer Rights (FTCR) ...
... athletes about ... generational health risk: Long-term steroid abuse causes significant ... bodily harm, BALTIMORE, Dec. ... to bring,the era of steroids and human growth hormone to an end, is exactly ...
... CHAPEL HILL, N.C., Dec. 14 Companies competing ... and bureaucratic,standards. Organizations have come to rely on ... requirements. But effective quality systems,don,t just spontaneously spring ... key to creating and maintaining a quality operation ...
... Ala., Dec. 14 HealthSouth,Corporation (NYSE: HLS ... with the United States Department of Justice on ... the Department of Health and Human,Services (HHS) to ... previous management team. The settlement amount of $14.2,million ...
... WASHINGTON, Dec. 14 Following is a statement,by ... Healthcare Products,Association (CHPA), regarding the recommendations of the ... on phenylephrine:, "Phenylephrine 10 mg is safe ... proven effective for nasal decongestion in multiple clinical ...
Cached Medicine News:Health News:Transtheoretical model may help to identify OSA patients' level of intention to exercise 2Health News:Transtheoretical model may help to identify OSA patients' level of intention to exercise 3Health News:Stem Cell Agency 'Disclosure' Makes Mockery of Claims of Openness and Transparency 2Health News:Stem Cell Agency 'Disclosure' Makes Mockery of Claims of Openness and Transparency 3Health News:Youth Impacted By Recent 'Mitchell Report' on Major League Baseball Steroid Abuse 2Health News:Integrating Quality into Business Systems for High Performance, Complimentary Excerpt Available from Best Practices, LLC 2Health News:HealthSouth Announces Final Agreement on Previously Disclosed Settlement with Federal Government 2Health News:Statement from the Consumer Healthcare Products Association on Today's FDA Advisory Committee Meeting on the Efficacy of Phenylephrine in the 10 Mg Oral Dose 2
... has application for use in the creation ... spaces such as the retroperitoneal, preperitoneal, and ... in surgical procedures requiring dissection of tissue. ... a quality conduit through a single leg ...
... VAD System includes three major components: Blood ... TLC-II Portable Driver. This system provides partial ... heart, with conventional therapy, is unable to ... To accomplish support, blood flows from the ...
... polyethylene glycol polymers that combine to form COSEAL ... bond to each other, as well as to ... a flexible, watertight seal that remains intact at ... pressure. It is completely resorbed by the body ...
The Icy catheter is inserted into the femoral vein and resides in the inferior vena cava. Saline flow within the balloons creates a proprietary vortex flow pattern which maximizes heat exchange with...
Medicine Products: